Lance Sloan MD in Lufkin, Texas

Home Texas Lufkin

Lance Sloan MD has Endocrinology as his primary medical specialty. Their primary office is: 504 S John Redditt Dr in Lufkin, Texas. There are 3 additional office locations for Lance Sloan MD that can be viewed towards the end of their profile. They attended University Of Texas Medical School At Houston and graduated in 1985 (around 39 years of experience). They are listed as doing telehealth appointments.

Lance A Sloan MD Office Phone and Directions

Lance Sloan MD
504 S John Redditt Dr
Lufkin, Texas 75904
936-634-8311

Patient Ratings
Please rate your experience with Lance Sloan MD below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 936-634-8311

Enter a starting address:

Healthcare Info for Lance Sloan MD

Additional Medical Specialties Include:
NEPHROLOGY

Medical School: University Of Texas Medical School At Houston
Graduation Year: 1985
The Primary Medical Specialty for Lance Sloan MD is listed as: Endocrinology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 39
PAC (PECOS ID)#: 8628022506
NPI #: 1588665228
NPI Created On: 08/03/2005
NPI Last Updated Listed as: 01/15/2014
Primary Taxonomy Code: 207RE0101X
License Number:
H0822
Listed Gender: Male

Insurance, Services, Charges

Forms of insurance accepted by include, but are not limited to:

Blue Cross Blue Shield
Medicare

They are listed as accepting new patients.

Languages spoken by staff include: Spanish.

Services and Procedures include:

Hemoglobin a1c level
Vaccine for influenza for injection into muscle
Dialysis services (4 or more physician visits per month), patient 20 years of age and older
Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours
Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
New patient office or other outpatient visit, typically 45 minutes
New patient office or other outpatient visit, typically 60 minutes
Established patient office or other outpatient visit, typically 5 minutes
Established patient office or other outpatient visit, typically 10 minutes
Established patient office or other outpatient visit, typically 15 minutes
Established patient office or other outpatient, visit typically 25 minutes
Established patient office or other outpatient, visit typically 40 minutes
Initial hospital inpatient care, typically 70 minutes per day
Subsequent hospital inpatient care, typically 25 minutes per day
Subsequent hospital inpatient care, typically 35 minutes per day
Prolonged office or other outpatient service first hour
Administration of influenza virus vaccine

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $88

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788428433

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Cardiovascular & Metabolism

Name of Drug #1: XARELTO

Open Associated Drug #1: 50458-580-30

Payments Total: $13

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788428423

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Cardiovascular & Metabolism

Name of Drug #1: XARELTO

Open Associated Drug #1: 50458-580-30

Payments Total: $9

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788428429

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Cardiovascular & Metabolism

Name of Drug #1: XARELTO

Open Associated Drug #1: 50458-580-30

Payments Total: $15

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Record ID:: 792517333

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: non-opioid analgesic

Name of Drug #1: Licart

Open Associated Drug #1: 71858-0305-5

Payments Total: $14

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 797209929

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: TEPEZZA

Name of Drug #1: TEPEZZA

Open Associated Drug #1: 75987-130-15

Payments Total: $23

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 797209933

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: TEPEZZA

Name of Drug #1: TEPEZZA

Open Associated Drug #1: 75987-130-15

Payments Total: $11

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 813529495

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: ANTIBIOTIC

Name of Drug #1: NUZYRA

Open Associated Drug #1: 71715-002-21

Payments Total: $14

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 813529499

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: ANTIBIOTIC

Name of Drug #1: NUZYRA

Open Associated Drug #1: 71715-002-21

Payments Total: $2,750

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third Party:: LANCE SLOAN,

Third party is a Charity:: No

Record ID:: 818624449

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Diabetes

Name of Drug #1: JARDIANCE

Open Associated Drug #1: 0597-0152-37

Payments Total: $1,100

Number of Payments:: 1

Form of Payment: Cash or cash equivalent

Third Party:: LANCE SLOAN,

Third party is a Charity:: No

Context of payment:: THE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT.

Record ID:: 818583041

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Diabetes

Name of Drug #1: JARDIANCE

Open Associated Drug #1: 0597-0152-37